These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

80 related items for PubMed ID: 21353540

  • 1. Synthesis and SAR studies of novel 2-(4-oxo-2-aryl-quinazolin-3(4H)-yl)acetamide vasopressin V1b receptor antagonists.
    Napier SE, Letourneau JJ, Ansari N, Auld DS, Baker J, Best S, Campbell-Wan L, Chan JH, Craighead M, Desai H, Goan KA, Ho KK, Hulskotte EG, MacSweeney CP, Milne R, Morphy JR, Neagu I, Ohlmeyer MH, Peeters AW, Presland J, Riviello C, Ruigt GS, Thomson FJ, Zanetakos HA, Zhao J, Webb ML.
    Bioorg Med Chem Lett; 2011 Mar 15; 21(6):1871-5. PubMed ID: 21353540
    [Abstract] [Full Text] [Related]

  • 2. Synthesis and SAR studies of novel 2-(6-aminomethylaryl-2-aryl-4-oxo-quinazolin-3(4H)-yl)acetamide vasopressin V1b receptor antagonists.
    Napier SE, Letourneau JJ, Ansari N, Auld DS, Baker J, Best S, Campbell-Wan L, Chan R, Craighead M, Desai H, Ho KK, MacSweeney C, Milne R, Richard Morphy J, Neagu I, Ohlmeyer MH, Pick J, Presland J, Riviello C, Zanetakos HA, Zhao J, Webb ML.
    Bioorg Med Chem Lett; 2011 Jun 15; 21(12):3813-7. PubMed ID: 21596563
    [Abstract] [Full Text] [Related]

  • 3. Identification and optimization of novel 2-(4-oxo-2-aryl-quinazolin-3(4H)-yl)acetamide vasopressin V3 (V1b) receptor antagonists.
    Letourneau JJ, Riviello CM, Li H, Cole AG, Ho KK, Zanetakos HA, Desai H, Zhao J, Auld DS, Napier SE, Thomson FJ, Goan KA, Morphy JR, Ohlmeyer MH, Webb ML.
    Bioorg Med Chem Lett; 2010 Sep 15; 20(18):5394-7. PubMed ID: 20719508
    [Abstract] [Full Text] [Related]

  • 4. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.
    Manning M, Stoev S, Chini B, Durroux T, Mouillac B, Guillon G.
    Prog Brain Res; 2008 Sep 15; 170():473-512. PubMed ID: 18655903
    [Abstract] [Full Text] [Related]

  • 5. Identification and optimisation of novel sulfonamide, selective vasopressin V1B receptor antagonists.
    Baker J, Bingham M, Blackburn-Munro R, Cai J, Craighead M, Gilfillan R, Goan K, Jaap D, Milne R, Morphy JR, Napier S, Presland J, Spinks G, Thomson F.
    Bioorg Med Chem Lett; 2011 Jun 15; 21(12):3603-7. PubMed ID: 21601454
    [Abstract] [Full Text] [Related]

  • 6. Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4.
    Cheng LL, Stoev S, Manning M, Derick S, Pena A, Mimoun MB, Guillon G.
    J Med Chem; 2004 Apr 22; 47(9):2375-88. PubMed ID: 15084136
    [Abstract] [Full Text] [Related]

  • 7. Tetrahydroquinoline sulfonamides as vasopressin 1b receptor antagonists.
    Scott JD, Miller MW, Li SW, Lin SI, Vaccaro HA, Hong L, Mullins DE, Guzzi M, Weinstein J, Hodgson RA, Varty GB, Stamford AW, Chan TY, McKittrick BA, Greenlee WJ, Priestley T, Parker EM.
    Bioorg Med Chem Lett; 2009 Nov 01; 19(21):6018-22. PubMed ID: 19800231
    [Abstract] [Full Text] [Related]

  • 8. The discovery of novel vasopressin V1b receptor ligands for pharmacological, functional and structural investigations.
    Guillon G, Derick S, Pena A, Cheng LL, Stoev S, Seyer R, Morgat JL, Barberis C, Gal CS, Wagnon J, Manning M.
    J Neuroendocrinol; 2004 Apr 01; 16(4):356-61. PubMed ID: 15089974
    [Abstract] [Full Text] [Related]

  • 9. Position 4 analogues of [deamino-Cys(1)] arginine vasopressin exhibit striking species differences for human and rat V(2)/V(1b) receptor selectivity.
    Guillon G, Pena A, Murat B, Derick S, Trueba M, Ventura MA, Szeto HH, Wo N, Stoev S, Cheng LL, Manning M.
    J Pept Sci; 2006 Mar 01; 12(3):190-8. PubMed ID: 16130178
    [Abstract] [Full Text] [Related]

  • 10. Pyrrolo[1,2-a]pyrazine and pyrazolo[1,5-a]pyrazine: novel, potent, and selective series of Vasopressin 1b receptor antagonists.
    Arban R, Bianchi F, Buson A, Cremonesi S, Di Fabio R, Gentile G, Micheli F, Pasquarello A, Pozzan A, Tarsi L, Terreni S, Tonelli F.
    Bioorg Med Chem Lett; 2010 Sep 01; 20(17):5044-9. PubMed ID: 20674355
    [Abstract] [Full Text] [Related]

  • 11. 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 2. Synthesis, chirality, and pharmacokinetics.
    Borthwick AD, Davies DE, Exall AM, Livermore DG, Sollis SL, Nerozzi F, Allen MJ, Perren M, Shabbir SS, Woollard PM, Wyatt PG.
    J Med Chem; 2005 Nov 03; 48(22):6956-69. PubMed ID: 16250654
    [Abstract] [Full Text] [Related]

  • 12. Synthesis and structure-activity relationship of 3-phenyl-3H-quinazolin-4-one derivatives as CXCR3 chemokine receptor antagonists.
    Storelli S, Verdijk P, Verzijl D, Timmerman H, van de Stolpe AC, Tensen CP, Smit MJ, De Esch IJ, Leurs R.
    Bioorg Med Chem Lett; 2005 Jun 02; 15(11):2910-3. PubMed ID: 15911279
    [Abstract] [Full Text] [Related]

  • 13. The characterization of a novel V1b antagonist lead series.
    Smethurst CA, Borthwick JA, Gaines S, Watson S, Green A, Schulz MJ, Burton G, Buson AA, Arban R.
    Bioorg Med Chem Lett; 2011 Jan 01; 21(1):92-6. PubMed ID: 21146408
    [Abstract] [Full Text] [Related]

  • 14. Lead optimization of 4-(dimethylamino)quinazolines, potent and selective antagonists for the melanin-concentrating hormone receptor 1.
    Kanuma K, Omodera K, Nishiguchi M, Funakoshi T, Chaki S, Semple G, Tran TA, Kramer B, Hsu D, Casper M, Thomsen B, Sekiguchi Y.
    Bioorg Med Chem Lett; 2005 Sep 01; 15(17):3853-6. PubMed ID: 16002290
    [Abstract] [Full Text] [Related]

  • 15. Synthesis and pharmacological investigation of novel 4-(2-methylphenyl)-1-substituted-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-ones as new class of H(1)-antihistaminic agents.
    Alagarsamy V, Rupeshkumar M, Kavitha K, Meena S, Shankar D, Siddiqui AA, Rajesh R.
    Eur J Med Chem; 2008 Nov 01; 43(11):2331-7. PubMed ID: 18031870
    [Abstract] [Full Text] [Related]

  • 16. Studies on quinazolines and 1,2,4-benzothiadiazine 1,1-dioxides. 8.1, 2 synthesis and pharmacological evaluation of tricyclic fused quinazolines and 1,2,4-benzothiadiazine 1,1-dioxides as potential alpha1-adrenoceptor antagonists.
    Chern JW, Tao PL, Wang KC, Gutcait A, Liu SW, Yen MH, Chien SL, Rong JK.
    J Med Chem; 1998 Aug 13; 41(17):3128-41. PubMed ID: 9703460
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
    Pena A, Murat B, Trueba M, Ventura MA, Wo NC, Szeto HH, Cheng LL, Stoev S, Guillon G, Manning M.
    J Med Chem; 2007 Feb 22; 50(4):835-47. PubMed ID: 17300166
    [Abstract] [Full Text] [Related]

  • 19. Potent CCR4 antagonists: synthesis, evaluation, and docking study of 2,4-diaminoquinazolines.
    Yokoyama K, Ishikawa N, Igarashi S, Kawano N, Masuda N, Hattori K, Miyazaki T, Ogino S, Orita M, Matsumoto Y, Takeuchi M, Ohta M.
    Bioorg Med Chem; 2008 Sep 01; 16(17):7968-74. PubMed ID: 18694645
    [Abstract] [Full Text] [Related]

  • 20. Novel 7-methoxy-6-oxazol-5-yl-2,3-dihydro-1H-quinazolin-4-ones as IMPDH inhibitors.
    Birch HL, Buckley GM, Davies N, Dyke HJ, Frost EJ, Gilbert PJ, Hannah DR, Haughan AF, Madigan MJ, Morgan T, Pitt WR, Ratcliffe AJ, Ray NC, Richard MD, Sharpe A, Taylor AJ, Whitworth JM, Williams SC.
    Bioorg Med Chem Lett; 2005 Dec 01; 15(23):5335-9. PubMed ID: 16202581
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.